Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175859-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $69.90 | |
| Ab175859-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $327.90 | |
| Ab175859-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $807.90 | |
| Ab175859-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,287.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Gemtuzumab (anti-CD33) - Primary antibody, specific to CD33, >95%, high purity, Human IgG4SP |
|---|---|
| Synonyms | CD 33 antibody; CD33 antibody; CD33 antigen (gp67) antibody; CD33 antigen antibody; CD33 molecule antibody; CD33_HUMAN antibody; FLJ00391 antibody; gp67 antibody; My9 antibody; Myeloid cell surface antigen CD33 antibody; Myeloid cell surface antigen CD33 |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | CD33 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | BINDING AGENT |
| Mechanism of action | BINDING AGENT of Myeloid cell surface antigen CD33 binding agent |
| Product Description | Gemtuzumab (anti-CD33) is a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab (anti-CD33) can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin. Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. |
| Isotype | Human IgG4SP |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 27.4 kDa (Light Chain) & 53.5 kDa (Heavy Chain), under reducing conditions; 175.3 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 220578-59-6 |
Gemtuzumab (anti-CD33) (Ab175859) - Flow Cytometry
Flow Cytometry analysis of THP-1 cells labelling CD33 (red) with Gemtuzumab (anti-CD33) (Ab175859). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG4SP. Black - Unlabelled control, cells without incubation with primary antibody.
Gemtuzumab (anti-CD33) (Ab175859) - SEC
The purity of Gemtuzumab (anti-CD33) (Ab175859) is more than 95% verified by HPLC.
Gemtuzumab (anti-CD33) (Ab175859) - ELISA
Immobilized Recombinant Human CD33 Protein (rp143966) at 2.0 μg/mL can bind Gemtuzumab (anti-CD33) (Ab175859). The ED₅₀ for this effect is 391.3 ng/mL.
Gemtuzumab (anti-CD33) (Ab175859) - ELISA
Immobilized Recombinant Human Siglec-3/CD33 Protein (rp169578) at 1.0 μg/mL can bind Gemtuzumab (anti-CD33) (Ab175859) with the EC₅₀ of 36.93 ng/mL.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F0900969 | Certificate of Analysis | Sep 06, 2023 | Ab175859 |
| ZJ23F0900970 | Certificate of Analysis | Sep 06, 2023 | Ab175859 |
